Marks: FDA open to us­ing sin­gle-arm stud­ies for ac­cel­er­at­ed ap­proval of rare dis­ease gene ther­a­pies

Pe­ter Marks, the FDA of­fi­cial who over­sees gene ther­a­pies, is again ad­vo­cat­ing for the use of ac­cel­er­at­ed ap­provals for gene ther­a­pies that treat rare dis­eases.

Marks, who is the di­rec­tor of the FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search, said Mon­day dur­ing a we­bi­nar or­ga­nized by the NYU Gross­man School of Med­i­cine that the FDA is “try­ing to be pa­tient-fo­cused.” Un­der Marks, the FDA has ap­peared more flex­i­ble with ac­cel­er­at­ed ap­provals and the kinds of tri­als and re­sults need­ed to bring rare dis­ease ther­a­pies to mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER